This is a mechanism module, not a specific disease. It models the conserved vascular-complication cascade that is downstream of, and shared by, every cause of chronic hyperglycemia; it deliberately does NOT model the type-specific routes into hyperglycemia (autoimmune beta-cell destruction, insulin resistance, undernutrition beta-cell impairment, monogenic beta-cell defects), which stay on the individual disease entries. Diabetes mellitus is represented in dismech as a Grouping over the distinct type entries (kb/groupings/Diabetes_Mellitus.yaml, owning MONDO:0005015) plus this shared mechanism module plus the per-type Disease entries; there is no blended umbrella pathophysiology graph. Disorder entries reference individual nodes via conforms_to (e.g., "diabetic_vascular_complications#Endothelial Dysfunction and Vascular Inflammation"). The key conformance target is the Endothelial Dysfunction and Vascular Inflammation central-effector node, the rate-limiting convergence point every hyperglycemic disorder funnels through. Conforming nodes in disorder files should include the corresponding cell types, biological processes, and causal edges, specialized to their disease context (e.g., a disease may elaborate the renal sub-cascade into glomerular, tubular, and fibrotic nodes, or the retinal/neural arms, beneath the module's collapsed Diabetic Microvascular and Macrovascular Injury effector). Worked conformers: Type I Diabetes, Type 2 Diabetes Mellitus, and Malnutrition-Related Diabetes Mellitus each declare a conforms_to edge onto the shared cascade. The drug-target design pattern: glucose-lowering and cardiorenal-protective therapy (here SGLT2 inhibitors) acts upstream on the Chronic Hyperglycemia trigger rather than on the downstream structural phenotype, reducing the whole complication cascade. Modules bind GO and CL terms only and do not use chemical (CHEBI) or disease (MONDO) term bindings; chemistry and disease concepts are described in prose, except in the treatments block where the therapeutic agent carries a CHEBI/NCIT identifier per the treatment schema.
Chronic Hyperglycemia
trigger
The shared, disorder-agnostic trigger. Sustained elevation of blood glucose — however it arises (absolute insulin deficiency, insulin resistance with beta-cell secretory failure, undernutrition-associated beta-cell impairment, or a monogenic beta-cell defect) — establishes the biochemical driver of long-term diabetic tissue injury. Because glucose enters insulin-independent vascular cells (endothelium, mesangium, Schwann cells, retinal pericytes) without downregulation, these cells experience the full intracellular glucose load and become the site of complication-initiating stress.
Downstream
-
Hyperglycemia-Induced Oxidative Stress and AGE-RAGE Activation
Chronic glucose excess increases reactive oxygen species and advanced glycation end-product formation, activating the canonical hyperglycemia-injury pathways.
Show evidence (3 references)
"According to the World Health Organization (WHO) diabetes mellitus is a chronic, metabolic disease characterized by elevated levels of blood glucose, which leads over time to damage to the heart, vasculature, eyes, kidneys and nerves."
Establishes chronic hyperglycemia as the central upstream driver of multiorgan diabetic complications (heart, vasculature, eyes, kidneys, nerves), the trigger of this module.
"Therefore, the life span benefit of Cana is likely to reflect blunting of peak glucose levels, because similar longevity effects are seen in male mice given acarbose, a diabetes drug that blocks glucose surges through a distinct mechanism"
Convergent pharmacological support for glycemic excursion as the pathogenic quantity in this trigger node: two drugs that lower postprandial glucose by unrelated mechanisms (SGLT2 inhibition and alpha-glucosidase inhibition) produce the same survival benefit in non-diabetic genetically heterogeneous mice. Extends the node beyond diabetes, since these animals are not diabetic. The benefit was male-specific, so this is not evidence of a uniform effect. Evidence source is MODEL_ORGANISM (UM-HET3 mice, NIA Interventions Testing Program).
"ACA at 1,000 ppm reduced lung tumors in males, diminished liver degeneration in both sexes and glomerulosclerosis in females, reduced blood glucose responses to refeeding in males, and improved rotarod performance in aging females, but not males."
Ties the glucose-excursion intervention to end-organ pathology in the same cohort: acarbose both blunted refeeding glucose responses and reduced glomerulosclerosis and liver degeneration, the kind of tissue injury this module's downstream nodes model. The endpoints are sex-discordant rather than co-occurring, and the snippet should not be read as showing that the glucose effect accompanied the renal one: the glucose response was reduced in males, glomerulosclerosis was diminished in females, and only liver degeneration improved in both sexes. That discordance is the caveat a curator should carry forward rather than reading it as general protection. Evidence source is MODEL_ORGANISM (UM-HET3 mice).
Hyperglycemia-Induced Oxidative Stress and AGE-RAGE Activation
amplifier
The amplifying step. Hyperglycemia raises mitochondrial superoxide production, which activates the five interlocking pathways of diabetic complications: the polyol pathway, advanced glycation end-product (AGE) formation, increased AGE-receptor (RAGE) expression and ligand signaling, protein kinase C (PKC) isoform activation, and hexosamine-pathway overload. AGE-RAGE engagement propagates a self-amplifying pro-inflammatory, pro-oxidant signal. This oxidative and glycative stress is the biochemical amplifier that converts elevated glucose into vascular-wall injury.
Downstream
-
Endothelial Dysfunction and Vascular Inflammation
Oxidative and glycative stress impair endothelial homeostatic signaling and drive inflammatory activation of the vessel wall.
Show evidence (2 references)
"The increase in O2− production activates the five major pathways involved in the pathogenesis of diabetes complications: enhancement of the polyol pathway, increased formation of advanced glycation end products (AGEs), increased expression of AGEs receptor and its activating ligands, activation..."
Directly identifies superoxide-driven activation of the polyol, AGE/RAGE, PKC and hexosamine pathways as the mechanistic amplifier of diabetic complications.
"Oxidative stress has been considered as a major hallmark for the pathogenesis and development of type 2 diabetes mellitus (T2DM)"
Supports oxidative stress as a major mechanistic hallmark amplifying diabetic pathophysiology.
Endothelial Dysfunction and Vascular Inflammation
central effector
The rate-limiting central effector and key conformance target. Oxidative and AGE-RAGE stress disrupt the endothelium's balanced release of vasodilator (e.g., nitric oxide) and vasoconstrictor mediators, altering the physicochemical properties of the vascular wall. The endothelium shifts to a vasoconstricted, prothrombotic, pro-inflammatory phenotype with platelet hyperreactivity and leukocyte recruitment. This endothelial dysfunction with vascular inflammation is the pivotal, disorder-agnostic convergence point: every cause of chronic hyperglycemia funnels through it to reach both micro- and macrovascular injury. This is the key conformance target of the module.
Downstream
-
Diabetic Microvascular and Macrovascular Injury
Endothelial injury and vascular inflammation damage small vessels of the kidney, retina and nerve and accelerate atherosclerosis of the large arteries.
Show evidence (1 reference)
"Endothelium plays an important role in the regulation of vascular tone and structure through a balanced release of endothelial-derived relaxing and contracting factors. This balance is altered in T2DM leading to alteration of the physicochemical properties of the vascular wall via endothelial..."
Establishes loss of balanced endothelial mediator release, with oxidative stress, platelet hyperreactivity and inflammation, as the pivotal intermediate event linking hyperglycemia to vascular complications.
Diabetic Microvascular and Macrovascular Injury
effector
The effector step where endothelial dysfunction becomes structural vascular disease. In the microvasculature, injury of the small vessels of the kidney (glomerular and peritubular capillaries), retina, and peripheral nerve produces the classic diabetic microvascular triad. In the macrovasculature, endothelial dysfunction and inflammation accelerate atherosclerotic plaque formation in the coronary, cerebral, and peripheral arteries. A disease entry may elaborate this collapsed node into organ-specific sub-cascades (e.g., renal hemodynamic dysregulation -> glomerular injury -> tubular injury -> renal fibrosis) beneath this shared effector.
Downstream
-
Diabetic End-Organ Complications
Sustained micro- and macrovascular injury produces the clinical diabetic end-organ complications.
Show evidence (2 references)
"Diabetic microvascular complications such as retinopathy, nephropathy, and neuropathy are primary causes of blindness, terminal renal failure, and neuropathic disorders in type 2 diabetes mellitus patients."
Identifies retinopathy, nephropathy and neuropathy as the microvascular injury pathways driven by diabetic small-vessel disease.
"T2DM leads to a two- to four-fold increase in the mortality rate of adults from heart disease and stroke and is associated with both micro- and macro-vascular complications, the latter consisting of accelerated atherosclerosis leading to severe peripheral vascular disease, premature coronary..."
Supports the macrovascular arm — accelerated atherosclerosis producing coronary, cerebrovascular and peripheral arterial disease.
Diabetic End-Organ Complications
consequence
The clinical end state of the module. Chronic micro- and macrovascular injury manifests as diabetic kidney disease (albuminuria progressing to chronic kidney disease and end-stage renal failure), diabetic retinopathy (a leading cause of acquired blindness), diabetic neuropathy (peripheral and autonomic), and atherosclerotic cardiovascular disease (coronary artery disease, stroke, and peripheral artery disease). These complications are the principal source of diabetes-related morbidity and premature mortality and are the shared consequence of the conserved chronic-hyperglycemia -> oxidative/AGE-RAGE stress -> endothelial dysfunction -> vascular injury chain.
Show evidence (2 references)
"According to the World Health Organization (WHO) diabetes mellitus is a chronic, metabolic disease characterized by elevated levels of blood glucose, which leads over time to damage to the heart, vasculature, eyes, kidneys and nerves."
Establishes damage to the heart, vasculature, eyes, kidneys and nerves as the end-organ consequence of chronic diabetes, the terminal node of this module.
"Diabetic microvascular complications such as retinopathy, nephropathy, and neuropathy are primary causes of blindness, terminal renal failure, and neuropathic disorders in type 2 diabetes mellitus patients."
Confirms retinopathy, nephropathy and neuropathy as the vision-, renal- and nerve-threatening clinical end-organ complications.
SGLT2 Inhibitor Cardiorenal Protection
Platform:
Small molecule
Sodium-glucose cotransporter-2 (SGLT2) inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower plasma glucose by increasing urinary glucose excretion, acting on the upstream Chronic Hyperglycemia trigger of this module. In large cardiovascular and renal outcome trials they reduce diabetic cardiovascular and kidney complications, illustrating the module's drug-target design pattern: acting on the upstream hyperglycemic driver (and, for this class, additional glucose-independent renal-hemodynamic effects) reduces the entire downstream vascular-complication cascade rather than treating an established end-organ phenotype.
Evidence: 1